Furthermore, ARHGAP39 potentially regulated the immune-related pathways, and affected the tumor-infiltrating immune cells, thus providing opportunities for the development of novel immunotherapies for breast cancer treatment. This evidence concerns the gene ARHGAP39 and breast cancer.